Characterization of D-Cyclin Proteins in Hematolymphoid Neoplasms: Lack of Specificity of Cyclins D2 and D3 Expression in Lymphoma Subtypes
暂无分享,去创建一个
Yasodha Natkunam | Robert J. Marinelli | Matthew W. Anderson | Ryan A Metcalf | I. Lossos | Y. Natkunam | Shuchun Zhao | A. Cherry | R. Metcalf | Izidore S Lossos | Shuchun Zhao | Matthew W Anderson | Zhi Shun Lu | Ilana Galperin | Robert J Marinelli | Athena M Cherry | Z. Lu | Ilana Galperin
[1] C. Sherr. G1 phase progression: Cycling on cue , 1994, Cell.
[2] I. Lossos,et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. , 2007, Blood.
[3] T. Chiles. Regulation and Function of Cyclin D2 in B Lymphocyte Subsets1 , 2004, The Journal of Immunology.
[4] Robert Tibshirani,et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Seto,et al. Selective usage of D-type cyclins in lymphoid malignancies , 1999, Leukemia.
[6] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[7] N. Harris,et al. Low Histologic Grade Follicular Lymphoma With High Proliferation Index: Morphologic and Clinical Features , 2005, The American journal of surgical pathology.
[8] Nigam H. Shah,et al. The Stanford Tissue Microarray Database , 2007, Nucleic Acids Res..
[9] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Wei Wei Wu,et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. , 2000, International immunology.
[11] B. Sander,et al. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. , 2008, American journal of clinical pathology.
[12] M. Raffeld,et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 , 2008, Leukemia.
[13] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[14] Yasodha Natkunam,et al. Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry , 2001, Modern Pathology.
[15] H. Pospíšilová,et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. , 2008, Blood.
[16] L. Staudt,et al. Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling , 2005 .
[17] Pierre Dubus,et al. Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.
[18] Yasodha Natkunam,et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.
[19] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[20] N. Harris,et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[22] R. Tibshirani,et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. , 2007, Blood.
[23] Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. , 2001, American journal of clinical pathology.
[24] W. Chan,et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.
[25] D. Rawlings,et al. Transitional B Lymphocyte Subsets Operate as Distinct Checkpoints in Murine Splenic B Cell Development1 , 2002, The Journal of Immunology.
[26] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[28] L. Staudt,et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.
[29] M. Du,et al. Cyclin D1‐positive diffuse large B‐cell lymphoma , 2008, Histopathology.
[30] G. Daley,et al. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. , 2002, Cancer research.
[31] L. de Leval,et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. , 2008, Blood.
[32] A. Rosenwald,et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. , 2005, Human pathology.
[33] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[34] L. Szekely,et al. Expression of cyclin D2 and D3 in lymphoid lesions , 1999, International journal of cancer.
[35] D. Weisenburger,et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. , 2006, Blood.